All In MedTech

Device Trial Radar · NCT07617584

NIRAF-Guided Parathyroid Identification During Thyroidectomy

Near-Infrared Autofluorescence-Guided Parathyroid Identification During Thyroidectomy

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jun 1, 2029

Study completion Dec 1, 2029

Sponsor

Lead sponsor
Ss. Cyril and Methodius University of SkopjeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Illinois at Urbana-Champaign
First posted
Jun 1, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates whether a wearable near-infrared autofluorescence (NIRAF) imaging system can help surgeons identify and preserve parathyroid glands during thyroid surgery. These small glands produce parathyroid hormone (PTH), which helps control blood calcium. The modified Meta Quest stereoscopic goggles display fluorescence naturally emitted by parathyroid tissue; no injected dye is used. The study has two components. Component A is a nonrandomized, 30-participant specimen-imaging and pathology-validation component. Component B is a randomized study with a target of 250 adults undergoing total or completion thyroidectomy. Participants in Component B are assigned equally to standard surgery or standard surgery with brief NIRAF imaging of the surgical field and the removed specimen. Clinically appropriate parathyroid rescue and autotransplantation are permitted. The primary randomized outcome is early biochemical hypoparathyroidism: a serum intact PTH concentration below the testing laboratory's assay-specific lower limit of normal, measured 12 to 24 hours after skin closure, with a target of 18 hours. Calcium levels, later parathyroid function, treatment requirements, surgical findings, and complications are also assessed. Follow-up lasts six months. Five research blood collections are scheduled: 1 to 2 days before surgery, 12 to 24 hours after surgery, six weeks, three months, and six months. An early safety assessment occurs 48 to 72 hours after surgery. Additional tests and visits are provided whenever clinically needed. A nested device-performance assessment records additional glands identified beyond the surgeon's initial white-light assessment and documented changes in surgical management attributable to NIRAF information. These findings are assessed separately from the randomized clinical outcomes.

Conditions

  • Hypocalcemia
  • Hypoparathyroidism
  • Thyroid Diseases
  • Goiter, Nodular
  • Thyroid Nodule
  • Thyroidectomy

Interventions

  • Wearable Near-Infrared Autofluorescence Imaging SystemDevice

    A modified Meta Quest head-mounted stereoscopic goggle system configured for label-free near-infrared autofluorescence imaging. The system delivers near-infrared excitation at approximately 780 nm and detects parathyroid autofluorescence centered near 800 nm. No injected dye or external contrast agent is administered. The device is used briefly after thyroid exposure for in vivo mapping and after thyroid resection for ex vivo specimen interrogation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Biochemical Hypoparathyroidism After Thyroidectomy (Component B)Time frame: 12 to 24 hours after completion of skin closure; target 18 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Clinic Hospital

    Skopje, North Macedonia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.